sdbrown

On a related-different axis, I've consistently seen on-prem GPUs running identical workloads ~35% faster than the same workloads on the same cloud hardware, regardless of intermediate infra stack layering/versioning choices. Weird but I'm not complaining!

Wasn't this part of the base thesis of "We Have Never Been Modern"?

Are you referring to Bruno Latour or the author of the post? If you're referring to Latour, I would strongly urge you to read "Laboratory Life", which is [as] clear and easy to read today as it was when I first encountered it nearly 20 years ago.

I don't see dilution anywhere on that page, and increasing volume of administration at a lower concentration to achieve the same effective dose does not alter the dose itself. You are not interpreting TI correctly.

Edit: further, to your comment about "prescription strength" nomenclature, look at section 14 of the Cialis/tadalafil prescribing information, IIRC, table of clinical studies, where they have the second two outcomes of the clinical studies broken down by dose. Efficacy increases pretty directly with increasing dose, and these are where the observed side effects show up. It seems like patients may well self-escalate. Maybe the OTC countries have public data on this?

Tadalafil (Cialis) is available as a generic in the United States. If you think "big pharma" is served by drugs going off-patent, you may want to re-evaluate your perspective.

If you want to get more reasonably unhappy with market exclusivity, look at Celgene's grip on thalidomide/lenalidomide/pomalidomide for the treatment of multiple myeloma.

How, in your view, does dilution change the therapeutic index of a chemical? If a drug is effective at 20 milligrams, but at 60 milligrams has a steep rise in the incidence of hypotension, how does taking that same 60 milligrams in a larger volume of filler (e.g. water, or spread across more physical pills) change the fact that you've just taken 60 milligrams?

To me it sounds dialed-in even on immediate landing. Different strokes!

Apologies -- tetrazine reacts principally with trans-cyclooctenes. So azide/DBCO would be the orthogonal group. To the best of my knowledge, those two pairs do not cross-react.

Tetrazine/DBCO is also pretty popular IIRC.

I feel like fingerprint/iris/retinal scanners would be a reasonable stop-gap here if only there was some way to deploy them cheaply. Does anyone know if such add-ons exist that might be made compatible with a 2FA system?

This is a fabulous convenience! The reach of this ready-to-go data will be much larger (in some directions) than the model and CASP results themselves.

I appreciate your comment; medication saved me from tanking what has been a relatively successful career.

However, they bring up a reasonable question, which is that of conflicts-of-interest. I do not now, nor have a I ever, received any compensation from a current or historical manufacturer of medications targeting ADHD. I do not anticipate receiving any such compensation in the future. However, I am married to a physician. (Side note: she also has ADHD. One of the smartest people I've ever met, but nearly failed her first USMLE because she couldn't execute on review/studying prior to the test. Went on meds and passed the rest of her exams with scores right in the middle of the distribution. The meds don't make us super-human, they just let us be normal.)